<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01992146</url>
  </required_header>
  <id_info>
    <org_study_id>MP_SM01_2013</org_study_id>
    <nct_id>NCT01992146</nct_id>
  </id_info>
  <brief_title>Effect of High-dose Naloxone Infusion on Pain and Hyperalgesia in Patients Following Groin-Hernia Repair.</brief_title>
  <official_title>Effect of High-dose Naloxone Infusion on Pain and Hyperalgesia in Patients Following Groin-Hernia Repair. A Randomized, Placebo-controlled, Double-blind Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have focused on the role of endogenous opioids on central sensitization.
      Central sensitization is known to be impaired or altered in chronic pain conditions, as
      fibromyalgia or chronic tension headache.

      Animal studies have shown reinstatement of mechanical hypersensitivity following naloxone
      administration after resolution of an injury. This suggests latent sensitization.

      In the present study, investigators hypothesize that a high-dose target-controlled naloxone
      infusion (total dose: 3.25 mg/kg) can reinstate pain and hyperalgesia 6-8 weeks after a
      unilateral primary open groin hernia repair procedure. Investigators aim to show that latent
      sensitization is present in humans and is modulated by endogenous opioids.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summated pain intensity</measure>
    <time_frame>1st session: 6-8 weeks after surgery; 2nd session: one week later</time_frame>
    <description>Change in pain ratings ([NRS,0-10] pain at rest + pain during transition from supine to standing position + pain during pressure (100 kPa) at injury site), assessed 6-8 weeks after unilateral, primary, open groin hernia repair following administration of naloxone/placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary hyperalgesia/allodynia</measure>
    <time_frame>1st session: 6-8 weeks after surgery; 2nd session: one week later</time_frame>
    <description>Change in secondary hyperalgesia area/allodynia at surgical site and at the mirror-site in the contralateral groin assessed 6-8 weeks after unilateral, primary, open groin hernia repair following administration of naloxone/placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pressure pain thresholds</measure>
    <time_frame>1st session: 6-8 weeks; 2nd session: one week later</time_frame>
    <description>Change in pressure pain thresholds at surgical site and at the mirror-site in the contralateral groin assessed 6-8 weeks after unilateral, primary, open groin hernia repair following administration of naloxone/placebo.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pain Catastrophizing Scale</measure>
    <time_frame>in the 1st session: 6-8 weeks after surgery</time_frame>
    <description>Patients fill out Pain Catastrophizing Scale before assessments on the first study day</description>
  </other_outcome>
  <other_outcome>
    <measure>Hospital Anxiety and Depression Scale</measure>
    <time_frame>in the 1st session: 6-8 weeks after surgery</time_frame>
    <description>Patients fill out Hospital Anxiety and Depression Scale before assessments on the first study day</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical Opiate Withdrawal Scale</measure>
    <time_frame>1st session: 6-8 weeks after surgery; 2nd session: one week later</time_frame>
    <description>Clinical Opiate Withdrawal Scale is filled out before and during naloxone/placebo administration in each experimental session</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Central Nervous System Sensitization</condition>
  <condition>Pain</condition>
  <condition>Hyperalgesia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Target-controlled naloxone-infusion (total dose: 3.25 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Change in Pain Ratings (NRS) at the surgical site and at the mirror-site in the contralateral groin six to eight weeks after unilateral herniotomy following administration of naloxone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Target-controlled naloxone-infusion</intervention_name>
    <arm_group_label>Target-controlled naloxone-infusion (total dose: 3.25 mg/kg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years and ≤ 65 years

          -  Signed informed consent

          -  Patients submitted to unilateral, primary inguinal, open herniotomy 6-8 weeks prior to
             study start.

          -  Open operating procedure a.m. Lichtenstein.

          -  Urin sample without traces of opioids (morphine, methadon, buprenorphine, codeine,
             tramadol, ketobemidone, oxycodone, hydromorphine, dextromethorphan)

          -  ASA I-II

          -  Body mass index (BMI): 18 &lt; BMI &lt; 30

        Exclusion Criteria:

          -  Volunteers , who do not speak or understand Danish

          -  Patients, who cannot cooperate with the investigation

          -  Patients who have had previous surgery in the groin region

          -  Patients with pain at rest &gt; 3 (NRS)

          -  Activity-related pain in the surgical field &gt; 5

          -  Allergic reaction against morphine or other opioids (including naloxone),

          -  Abuse of alcohol or drugs - according to investigator's evaluation

          -  Use of psychotropic drugs (exception of SSRI)

          -  Neurologic or psychiatric disease

          -  Chronic pain condition

          -  Regular use of analgesic drugs

          -  Skin lesions and tattoos in the assessment areas

          -  Nerve lesions in the assessment sites (for instance, after trauma, disc herniation,
             etc.)

          -  Use of prescription drugs 1 week before the trial

          -  Use of over-the-counter drugs 48 hours before the trial
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mads U Werner, M.D., D.M.Sc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mads U Werner, M.D., D.M.Sc.</last_name>
    <role>Study Director</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mads U Werner, M.D., D.M.Sc.</last_name>
    <phone>+45 3545 7618</phone>
    <email>mads.u.werner@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Willum, A.P.R.N</last_name>
    <phone>+45 3545 7623</phone>
    <email>anne.willum@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Multidisciplinary Pain Center, 7612, HOC, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mads U Werner, M.D., D.M.Sc</last_name>
      <phone>+45 3545 7618</phone>
      <email>mads.u.werner@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anne Willum, A.P.R.N</last_name>
      <phone>+45 3545 7623</phone>
      <email>anne.willum@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Anne Willum, R.N.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anders Springborg, M.S.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2013</study_first_submitted>
  <study_first_submitted_qc>November 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2013</study_first_posted>
  <last_update_submitted>November 23, 2015</last_update_submitted>
  <last_update_submitted_qc>November 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Mads Werner</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>central sensitization</keyword>
  <keyword>endogenous opioids</keyword>
  <keyword>humans</keyword>
  <keyword>latent sensitization</keyword>
  <keyword>naloxone</keyword>
  <keyword>open groin hernia repair</keyword>
  <keyword>pain</keyword>
  <keyword>randomized controlled trial</keyword>
  <keyword>secondary hyperalgesia</keyword>
  <keyword>target-controlled infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hernia</mesh_term>
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

